Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 4/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25334166 | 0.89 | JAK2 (0.40) | EPHX2 | |
| SCHEMBL31614261 | 0.80 | KCNH2 (0.40) | LMNAHPGDSMN1; SMN2KDM4ENPC1 | |
| SCHEMBL23068992 | 0.79 | NOTUM (0.38) | ACHEPTGER1KDM4EALDH1A1BTK | |
| SCHEMBL26664816 | 0.74 | OPRK1 (0.36) | ACHELMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL25334059 | 0.71 | EPHX2 (0.44) | EPHX2LMNASMN1; SMN2PTGER1KDM4E | |
| SCHEMBL25104276 | 0.70 | ERN1 (0.38) | EPHX2KDM4EBTKNOTUM | |
| SCHEMBL1357926 | 0.69 | SMN1; SMN2 (0.51) | LMNAHPGDSMN1; SMN2KDM4ENPC1 | |
| SCHEMBL20689124 | 0.69 | KDM5A (0.42) | KDM5A | |
| SCHEMBL25111998 | 0.69 | AADAT (0.31) | KDM4EALDH1A1AADAT | |
| SCHEMBL31729323 | 0.69 | PDE4D (0.32) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4471029-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | Suzhou Genhouse Bio Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240391923-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | SUZHOU GENHOUSE BIO CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| CN-118541371-A | Methionine adenosyltransferase 2A inhibitors for the treatment of MTAP deleted cancers | 勤浩医药（苏州）有限公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023143356-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | 勤浩医药（苏州）有限公司 | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391923-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | MAT2B, MAT2A, MAT1A | EPHX2 1423/4885ACHE 4257/4885LMNA 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.